Sensory Rehabilitation in Chemotherapy Induced Peripheral Neuropathy (CIPN)

NCT ID: NCT05382520

Last Updated: 2024-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-01

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Physiotherapist research about Sensory rehabilitation in chemotherapy induced peripheral neuropathy (CIPN) with the aid of questioners and physiotherapy practice

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CIPN

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Prospective Pilot and Feasibility study
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Explicit sensory retraining for lower extremity in individuals with CIPN

Explicit sensory retraining for lower extremity function (pain, sensory, balance, gait). five one-hour sessions, a week apart: Pre-Post assessment sessions with 3 treatment sessions in between. Home exercise assigned.

Group Type EXPERIMENTAL

Questionares and practice

Intervention Type DIAGNOSTIC_TEST

Questionares and practice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionares and practice

Questionares and practice

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 and over who suffer from chemotherapy-induced neuropathy (CIPN), according to the patient's report, more than 3 months since the end of the chemotherapy treatment.

Exclusion Criteria

1. Sensory damage / neuropathy that existed even before the start of chemotherapy
2. Incidents of recurrent falls even before the start of chemotherapy (over 2 falls for 6 months)
3. Central nervous system involvement
4. Major pre-morbid orthopedic lower limb impairment
5. Hebrew language not sufficient for assessment and treatment
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zefat Academic College

OTHER

Sponsor Role collaborator

Assaf-Harofeh Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rotem Merose

Breast Oncologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rotem Merose, Dr.

Role: PRINCIPAL_INVESTIGATOR

Assaf Harofee MC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shamir medical center

Beer Yaaqov, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hadas Ofek

Role: CONTACT

972544666412

Nicole Asraf

Role: CONTACT

972544699403

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nicole Asaraf

Role: primary

972-544699403

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0057-22-ASF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.